<DOC>
	<DOCNO>NCT00809289</DOCNO>
	<brief_summary>This Phase 1 study assess effect esreboxetine heart . In particular effect specific electrocardiogram ( ECG ) measurement call QTc measure .</brief_summary>
	<brief_title>Phase 1 Thorough QT ( TQT ) Study Young Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male female subject age 18 55 year Body mass Index approximately 18 30kg/m2 Informed consent document sign subject legally acceptable representative Subjects willing able comply schedule visit , treatment test , laboratory test , study procedure Evidence history clinically significant haematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic psychiatric , neurologic allergic disease clinical finding screen Conditions possibly affect drug absorption 12lead ECg demonstrate QTc &gt; 450ms clinically significant abnormality screen Positive urine drug screen Hypersensitivity moxifloxacin Unwilling unable comply lifestyle guideline protocol Treatment investigational drug within 3 month 5 half life ( whichever longer ) precede first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Thorough QT/QTc study</keyword>
</DOC>